Board logo

subject: Aarkstore Enterprise---johnson & Johnson (jnj) - Financial And Strategic Analysis Review [print this page]


Aarkstore Enterprise---johnson & Johnson (jnj) - Financial And Strategic Analysis Review

Johnson & Johnson (J&J) is engaged in the manufacture and sale of a broad range of healthcare products worldwide. The company focuses on the development of products related to health and well-being. J&J operates through three business segments, namely, Consumer, Pharmaceuticals, and Medical Devices and Diagnostics. The companys Consumer segment offers a wide range of health and personal care products in the beauty, oral care, baby care, womens health and over-the-counter categories. Through its Pharmaceuticals segment, the company focuses on five therapeutic areas, namely, Neuroscience, Cardiovascular Disease and Metabolism, Immunology, Oncology and Infectious Disease.

Table of Contents :

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Section 1 - About the Company 5

Johnson & Johnson - Key Facts 5

Johnson & Johnson - Key Employees 6

Johnson & Johnson - Key Employee Biographies 7

Johnson & Johnson - Major Products and Services 8

Johnson & Johnson - History 11

Johnson & Johnson - Company Statement 15

Johnson & Johnson - Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Section 2 - Company Analysis 28

Johnson & Johnson - Business Description 28

Business Description - Consumer 28

Consumer - Overview 28

Consumer - Financials 28

Consumer - Market View 29

Consumer - Key Strategies 29

Consumer - Technology 29

Business Description - Medical Devices and Diagnostics 29

Medical Devices and Diagnostics - Overview 29

Medical Devices and Diagnostics - Financials 29

Medical Devices and Diagnostics - Market View 29

Medical Devices and Diagnostics - Key Strategies 30

Medical Devices and Diagnostics - Technology 30

Business Description - Pharmaceutical 30

Pharmaceutical - Overview 30

Pharmaceutical - Financials 30

Pharmaceutical - Market View 30

Pharmaceutical - Key Strategies 31

Pharmaceutical - Technology 31

Johnson & Johnson - SWOT Analysis 32

SWOT Analysis - Overview 32

Johnson & Johnson - Strengths 32

Strength - Strong Liquidity Position 32

Strength - Diversified Product Offerings 32

Strength - Widespread Geographical Presence 32

Strength - Strong In-house Research Capabilities 33

Johnson & Johnson - Weaknesses 33

Weakness - Illegal Promotion of Topamax 33

Weakness - Declining Market Share in the Sector 33

Weakness - Underperforming Pharmaceuticals Segment 33

Weakness - Patent Expiries 34

Weakness - Product Recalls 34

Johnson & Johnson - Opportunities 34

Opportunity - Changing Demographics 34

Opportunity - Growth in the Prevalence of Cancer 34

Opportunity - Global Pharmaceutical Market 35

Opportunity - New Product Launches and Strong Pipeline 35

Opportunity - Strategic Acquisitions 35

Johnson & Johnson - Threats 36

Threat - Increased Pricing Control 36

Threat - Competitive Pressures 36

Threat - Regulatory Requirements 36

Threat - Litigation and Legal Claims 36

Johnson & Johnson - Key Competitors 37

Section 3 - Company Financial Ratios 38

Financial Ratios - Capital Market Ratios 38

Financial Ratios - Annual Ratios 38

Performance Chart 40

Financial Performance 40

Financial Ratios - Interim Ratios 41

Financial Ratios - Ratio Charts 42

Section 4 - Companys Recent Developments 43

Jul 20, 2010: Johnson & Johnson Reports Sales Of $15.33 Billion In Q2 2010 43

Jul 20, 2010: Johnson & Johnson Reports Net Income Of $3.4 billion For Q2 2010 43

Jul 19, 2010: FDA Inspects J&Js Lancaster Manufacturing Unit 43

Jul 19, 2010: Johnson & Johnson Appoints E. L. Davis To Board 43

Jul 19, 2010: Johnson & Johnson Appoints Ian Davis To Board 44

Jul 15, 2010: J&J To Cut 300 Jobs At Pennsylvania Facility 44

Jun 03, 2010: Johnson & Johnson Highlights Growth Strategies For MD&D Segment 44

Apr 20, 2010: J&J Announces Rejection Of Application For Sedasys System By FDA And Provides Updates Of Pipeline Products 46

Apr 20, 2010: J&J Q1 Sales Increase Due To Favourable Currency Exchange Rates 46

Apr 20, 2010: Johnson & Johnson Reports Net Earnings Of $4.5 Billion In Q1 2010 46

Section 5 - Appendix 48

Methodology 48

Ratio Definitions 48

About GlobalData 52

Contact Us 52

For more information please contact :

http://www.aarkstore.com/reports/Johnson-Johnson-JNJ-Financial-and-Strategic-Analysis-Review-62675.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore Enterprise




welcome to Insurances.net (https://www.insurances.net) Powered by Discuz! 5.5.0   (php7, mysql8 recode on 2018)